Restoration of a functional antiviral immune response to chronic HBV infection by reducing viral antigen load: if not sufficient, is it necessary?

ABSTRACT

The prolonged viral antigen stimulation is the driving force for the development of immune tolerance to chronic hepatitis B virus (HBV) infection. The sustained reduction of viral proteins may allow for the recovery and efficient activation of HBV-specific T and B cells by immune-stimulating agents, checkpoint blockades and/or therapeutic vaccinations. Recently, several therapeutic approaches have been shown to significantly reduce intrahepatic viral proteins and/or circulating HBV surface antigen (HBsAg) with variable impacts on the host antiviral immune responses in animal models or human clinical trials. It remains to be further investigated whether reduction of viral protein expression or induction of intrahepatic viral protein degradation is more efficacious to break the immune tolerance to chronic HBV infection. It is also of great interest to know if the accelerated clearance of circulating HBsAg by antibodies has a long-term immunological impact on HBV infection and disease progression. Although it is clear that removal of antigen stimulation alone is not sufficient to induce the functional recovery of exhausted T and B cells, accumulating evidence suggests that the reduction of viral antigen load appears to facilitate the therapeutic activation of functional antiviral immunity in chronic HBV carriers. Based on a systematic review of the findings in animal models and clinical studies, the research directions toward discovery and development of more efficacious therapeutic approaches to reinvigorate HBV-specific adaptive immune function and achieve the durable control of chronic HBV infection, i.e. a functional cure, in the vast majority of treated patients are discussed.

Introduction

Hepatitis B virus (HBV) chronically infects 257 million people worldwide and causes 800,000 deaths annually due to cirrhosis and hepatocellular carcinoma (HCC). Treatment of chronic hepatitis B (CHB) with nucleos(t)ide analogue (NUC) viral DNA polymerase inhibitors, such as entecavir and tenofovir, alone or in combination with pegylated alpha-interferon (IFN-α), can potently inhibit viral replication and prevent liver disease progression, but fails to induce a durable off-drug control of HBV infection in the majority of treated patients [1]. The reason for the failure of cure is that the currently available antiviral drugs cannot eliminate or inactivate viral covalently closed circular DNA (cccDNA), a nuclear viral replication intermediate that serves as the template for the transcription of viral RNAs. cccDNA is the most stable viral replication intermediate and resource of viral replication rebound after the termination of antiviral therapy [2]. In fact, even the clinical resolution of acute HBV infection is not the complete eradication of HBV cccDNA from the infected individuals, but a constant suppression of residual HBV infection by the immune surveillance of HBV-specific T and B cells [3]. This is evident by the reactivation of HBV replication under immunocompromised conditions even decades after clinical resolution of acute HBV infection [4]. Apparently, although the eradication of cccDNA from the infected individuals, the virological cure, is an ideal therapeutic endpoint, it is difficult to achieve. Instead, the therapeutic goal proposed by the world-leading professional associations, the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of Liver Disease (EASL), is to mimic the natural resolution of acute HBV infection by restoration or reconstitution of a functional antiviral immune response to durably control the chronic HBV infection, i.e. the functional cure of CHB, as indicated by the seroclearance of HBsAg, with a finite duration of therapies [5].

The outcomes and pathogenesis of HBV infection are determined by host antiviral immune responses

Unlike many other viruses that activate vigorous host cellular responses and kill the infected cells, HBV is a stealthy, non-cytopathic virus that does not activate a detectable “conventional” innate immune response and cellular transcriptome change in infected hepatocytes [6–8]. HBV infection of humans can be either resolved within six months (transient/acute) or persistent (chronic) for decades. The acute infection can be asymptomatic or causes hepatitis, which is generally mild and self-limited, but occasionally life-threatening fulminant hepatitis. Chronic HBV infection usually experiences four clinical stages: the initial phase of high viral load with no liver disease (immune tolerant or non-inflammatory phase) to active liver disease stage with HBeAg to anti-HBe seroconversion (immune clearance phase), followed by the inactive phase with a low viral replication and minimal liver diseases. Some of the inactive HBV carriers may revert to an immune reactivation phase with recurrent liver diseases and increased viral load years later [9].

Because HBV infection of hepatocytes does not directly induce cytopathic effects, the outcomes and pathogenesis of HBV infection are primarily determined by the nature and strength of host antiviral adaptive immune responses. Specifically, clinical studies showed that the resolution of acute HBV infection is associated with vigorous polyclonal CD8+ cytotoxic T lymphocyte (CTL) response and induction of antibodies against viral surface antigen [10]. Mechanistically, in addition to the killing of infected hepatocytes, CTLs also non-cytolytically cure the viral infected hepatocytes by cytokine-induced antiviral responses that suppress viral replication and eliminate/inactivate cccDNA [11,12]. Antibodies against HBsAg become detectable after the clearance of circulating HBsAg and work together with HBV-specific CD4+ and CD8+ memory T cells to control the residual HBV after apparent clinical resolution of an acute HBV infection over decades. Pathologically, the necrotic liver inflammation, i.e. hepatitis, during HBV infection is considered as the consequence of adaptive cellular immune responses, particularly CTLs, against HBV-infected hepatocytes [11]. Obviously, the balance between non-cytopathic and cytopathic effects of HBV-specific CD8+ T cells as well as the dynamics of immune response-induced hepatocyte killing/regeneration are critical in mediating HBV control without massive liver damage [13]. However, a recent study in HBV-infected chimpanzees indicates that the humoral immune response against viral proteins, particularly core protein, may play a critical role in the pathogenesis of severe or fulminant hepatitis [14].

Compared to those with acute infection, patients with chronic HBV infection are associated with the functional exhaustion or depletion of viral antigen-specific T cells [10,15] and atypical HBsAg-specific memory B cells deficient in the production of antibodies [16,17]. The immune tolerance or exhaustion of HBV-specific T and B cells is induced by continued stimulation of viral antigens in the setting of persistent viral replication. However, the mechanisms underlying the dysfunction of HBV-specific T and B cells are still not completely understood. It had been shown that although HBV-specific CD4+ and CD8+ T cells responses are initially induced, the persistence of viral antigens drives the differentiation of activated T cells to a functionally exhausted stage deficient in cytokine production, cytotoxicity and proliferative capacities [18,19]. The excessive antigen stimulation not only induces epigenetic reprogramming of CD8+ T cell gene regulation that reduce the expression of cytokines and effector molecules, but also induce the expression of multiple inhibitory receptors, such as programmed cell death protein (PD1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) [20,21] (Figure 1). Meanwhile, over-expression of several checkpoint receptor ligands, such as PD-L1 and galectin-9, has been observed on circulating and intrahepatic antigen-presenting cells and on liver resident Kupffer cells (KCs), respectively [22]. The interaction of these co-inhibitory receptors with their respective ligands inhibits the signal transduction of T-cell receptor (TCR) and co-stimulatory receptors and induces the expression of inhibitory genes [23]. Recently, it was reported that the thymocyte selection-associated high mobility group-box protein (Tox) plays a critical role in the development and maintenance of exhausted T lymphocytes [24]. Cell biological analyses also revealed that the exhausted T cells displayed mitochondrial dysfunction and metabolic reprogramming [25] and are more prone to apoptosis mediated by the up-regulation of the death receptor TRAIL-2 and the pro-apoptotic mediator BIM [26,27]. Although the excessive viral antigen is the primary driver of T and B cells exhaustion, dysfunction of antigen presentation cells, limited CD4+ T cell help, suppression by regulatory T cells, myeloid-derived suppressor cells (MDSC) and immunosuppressive cytokines such as IL-10 and transforming growth factor β (TGF-β) also favour the induction of T and B cell exhaustion [19,28,29].

Figure 1.

.#Therapeutic strategies to restore the functional T cell immune response. Activation of CD8+ T cells requires MHC-I presentation of antigenic peptide to TCR and co-stimulatory (such as CD80/CD86-CD28 engagement) and cytokine signaling. Excessive TCR stimulation induces the expression of co-inhibitory receptors on T cells. Activation of co-inhibitory receptors induces inhibitory gene expression and functional exhaustion of T cells. Mitochondrial dysfunction and extensive reprogramming of cell metabolism also contribute to the functional exhaustion of T cells. Four therapeutics strategies for restoration of exhausted CD8+ T cell are proposed.

Therapeutic strategies to restore a functional adaptive immune response in chronic hepatitis B patients

Understanding the mechanism of HBV-specific T and B cell exhaustion is the basis for the development of therapeutics to restore the functions of exhausted cells. As illustrated in Figure 1, it has been demonstrated that disrupting the interaction of co-inhibitory receptors with their ligands, i.e. checkpoint blockade, can significantly reinvigorate the cytokine production and proliferation potential of exhausted T cells in vitro [18,21,30,31]. A phase 1b clinical trial of PD1 blockade with nivolumab in HBeAg negative chronically HBV-infected patients showed a modest decline of HBsAg in most of the patients, while one patient achieved a sustained HBsAg seroclearance [16,32]. In addition to the checkpoint blockade therapies, studies in transgenic mice also demonstrated that activation of CD40-mediated co-stimulatory pathway rescued HBV-specific CD8+ T cells from PD-1-mediated exhaustion in HBV transgenic mice [33]. Moreover, improvement of mitochondrial function and correction of impaired metabolism of exhausted T cells, stimulation of antigen presentation cells (APCs) with the ligands of pattern recognition receptors (PRRs) and inhibition of Treg functions also partially restore the cytotoxicity and cytokine production capacities of exhausted HBV specific CD8+ T cells in vitro or in vivo [21,30,34]. However, the exhausted T cells are phenotypically heterogeneous and epigenetically reprogrammed extensively [35–37]. It is unlikely that the immunological functions of exhausted T and B cells can be completely restored by targeting a single molecular pathway.

Because of the critical role of excessive viral antigen stimulation in the induction of T and B cell exhaustion, reducing the viral proteins in hepatocytes and/or viral antigen loads in circulation, including HBsAg and HBeAg, had been considered as a prerequisite for the functional recovery of exhausted immune cells in CHB patients (Figure 1). In support of this hypothesis, it was reported that the functionality of HBV-specific T cells in CHB patients inversely correlates to the levels of HBsAg antigenemia and viral loads [38,39]. In addition, although the long-term therapies with nucleos(t)ide analogues do not generally lower serum HBsAg levels, a partial recovery of HBV-specific T cell function had been observed in patients receiving the therapies [40]. A plausible explanation for this finding is the significant reduction of viral proteins other than HBsAg, due to the significant reduction of cccDNA after the long-term suppression of viral DNA replication [41]. Moreover, pegylated IFN-α treatment of HBeAg- negative CHB patients did not induce the functional recovery of exhausted HBV-specific CD8 T cell response, but the decrease of viral loads was associated with an increase in the frequency of circulating CD56bright NK cells, increased expression of the activatory receptor NKp46 and the cytotoxic receptor TRAIL by NK cells and recovery of their IFN-γ production [42]. However, the frequency and function of HBsAg-specific B cells are partially restored in CHB patients upon pegylated IFN-α treatment-induced loss of HBsAg and anti-HBs seroconversion [43]. In addition, the functional cure rate of pegylated IFN-α treatment is significantly higher in patients with lower levels of HBsAg [44]. It is thus conceivable that the prolonged reduction of viral proteins may allow for a more profound recovery of HBV-specific T and B cells. However, clinical studies in CHB patients treated with drugs that are capable of reducing one or multiple viral proteins are required to directly prove the concept of whether reduction of viral antigen production or acceleration of viral protein degradation improves the function of HBV-specific T and/or B cells. It is also important to determine the viral antigens and the magnitudes of their reduction required for the restoration of T cell functions. Currently, three therapeutic modalities, including small interference RNA (siRNA) [45], antisense oligonucleotides (ASOs) [46] and small molecular drugs that induce viral RNA degradation [47], have been demonstrated in animal models or human clinical trials to significantly reduce the expression of multiple viral proteins and suppress viral replication. In addition, inhibitors of HBsAg secretion and monoclonal antibodies against HBsAg that can reduce circulating HBsAg are also under preclinical and clinical development. These clinical studies provide a unique opportunity to evaluate the impact of reducing intrahepatic and/or circulating HBV proteins on the functional status of HBV-specific T and B cells and their responses to immunothereapeutics. It is our hope that the knowledge, including the success and failure, learned from these clinical trials will ultimately help the discovery of feasible therapeutic approaches to restore a functional antiviral immune response for the functional cure of CHB.

Effects of reducing intrahepatic viral protein expression and/or circulating HBsAg on antiviral immune responses in mouse models

HBV transgenic mice lineage 1.3.32 contain a single copy of the terminally redundant 1.3mer HBV ayw genome integrated into the mouse chromosomal DNA [48]. HBV RNA transcription turns on progressively during the early postnatal liver development through gradual demethylation of the integrated viral genomic DNA and reaches maximal level at approximately 4 weeks after birth [49]. The early postnatal activation of HBV replication in the hepatocytes mimics neonate infection of HBV, which attributes to the most majority of chronic HBV infection in humans. Therefore, this transgenic mouse line had been extensively used in studying the mechanism of HBV-specific immune tolerance and immune control of HBV infection [50]. In addition, persistent replication of HBV in mice can also be established by transduction of HBV replicons via recombinant adenoviruses [51] or adenovirus-associated viruses (AAV) [52] as well as hydrodynamic injection of plasmid-based HBV replicons or recombinant cccDNA-like molecules [53]. Although these mouse models do not support dynamic HBV infection/dissemination and viral RNA transcription is not from authentic cccDNA, they provide convenient immune-competent small animal models to study host immune response to HBV infection.

In order to determine the role of circulating and intrahepatic HBsAg in the induction of CD8+ T cell exhaustion, Fumagalli and colleagues reported recently that serum HBsAg clearance induced by either spontaneous seroconversion or therapeutic monoclonal antibodies has only a minimal effect on the expansion of HBV-specific naive CD8+ T cells undergoing intrahepatic priming [54]. Interestingly, another study by this research group with transgenic mice expressing high level of HBcAg in almost all the hepatocytes and mice expressing lower level of HBcAg in approximately 10% of hepatocytes by adenoviral transduction showed that adoptively transferred HBcAg-specific naïve CD8+ T cells failed to differentiate into effector CTLs in mice expressing either high or low levels of HBcAg in hepatocytes [50]. However, the adoptively transferred HBcAg-specific naïve CD8+ T cells efficiently develop into effectors CTLs in mice transduced with recombinant replication-defective lymphocytic choriomeningitis virus (LCMV)-based vectors expressing HBV core protein in Kupffer cells (KCs) and hepatic dendritic cells (DCs) [50]. Because HBcAg cannot be secreted into circulation, these findings again clearly indicate that expression of viral antigen in hepatocytes is tolerogenic due to the lack of sufficient costimulatory signals and reduction of HBcAg expression in hepatocytes by more than 10 folds cannot prevent the induction of CD8+ T cell tolerance. However, it was found that treatment of HBV transgenic mice with type I IFN or IL-2 can rescue, at least in part, the development of the adoptively transferred HBV-specific naïve CD8+ T cells to functional effectors CTLs [50, 55]. These findings imply that IFN-α or pattern recognition receptor (PRR) agonist therapy of CHB may activate host antiviral immune response via partially rescuing the functional development of hepatocyte-primed CTLs (Figure 1).

However, a recent report by Michler et al showed that reduction of HBV viral protein expression by siRNA, but not the inhibition of viral replication by entecavir treatment, in HBV transgenic mice or AAV-HBV transduced mice enhanced the activation of polyclonal HBV-specific CD8+ effectors T cells and induction of neutralizing antibodies by a therapeutic vaccination regimen for durable control of HBV replication [56]. In addition, depletion of circulating HBsAg from AAV-HBV transduced mice by a monoclonal anti-HBsAg antibody enabled the activation of HBsAg-specific CD4+ T cells and induction of neutralizing antibody by subsequent Engerix-B vaccination. Moreover, TLR9 agonist-adjuvanted Engerix-B vaccination induced the clearance of HBV in both serum and liver [57]. These studies indicated that although the clearance of circulating HBsAg and reduction of hepatic viral protein by more than 10 fold cannot restore the functional development of hepatocyte-primed CD8+ T cells, it does allow the activation of antiviral adaptive immune responses by vaccination for efficient control of HBV infection in mice.

Breaking the immune tolerance to chronic WHV infection in woodchucks

Similar to HBV infection of humans, adulthood woodchuck hepatitis virus (WHV) infection is generally transient and resolved within 24 weeks, whereas congenital and neonate WHV infection usually results in life-long persistent infection and development of hepatocellular carcinoma in almost 100% of infected woodchucks within 3 years [58]. Woodchuck model had been used extensively to investigate the mechanism of immunological resolution of acute HBV infection and evaluate therapeutics for the cure of chronic HBV infection. Particularly, the demonstration of sustained suppression of viral replication and WHsAg to anti-WHs seroconversion with the TLR-7 agonist GS-9620 in a subset of WHV chronically infected woodchucks ignited the hope for the functional cure of CHB by PRR agonist therapy [59]. However, the following studies in chimpanzees and clinical trials showed limited efficacy of GS-9620 in tolerable dosing conditions [60,61]. Recently, it was discovered that a small molecular inhibitor (RG7834) of host cellular noncanonical poly(A) polymerases 5 and 7 (PAPD5 and PAPD7) can induce HBV mRNA degradation and subsequently inhibit viral replication and expression/secretion of multiple viral proteins [62]. Treatment of chronically WHV-infected woodchucks with RG7834 alone or in combination with entecavir and pegylated woodchuck IFN-α for 14 weeks reduced serum WHsAg by 2.57 or 5 log10, and WHV DNA by 1.71 or 7.45 log10 from baseline, respectively [63]. However, after termination of therapy, both WHsAg and WHV DNA levels rebounded, suggesting that such dramatic reductions of intrahepatic viral protein expression and circulating WHsAg are not sufficient to restore a functional antiviral immune response for the durable control of viral infection. It will be interesting to determine in this animal model with these therapeutic regimens the extents and durations of viral protein expression reduction that are required for the activation of a functional antiviral immune response by the variety of therapeutic vaccination strategies. It is also interesting to test whether reduction of viral antigen load will potentiate the therapeutic efficacy of TLR7/8 agonists.

Restoration of functional immune response in CHB patients

Targeted degradation of HBV mRNA by RNA interference (RNAi) or antisense oligonucleotides (ASOs) have been achieved not only in animal models but also in humans in clinical trials. Due to the extensive sequence overlaps of HBV RNA transcripts, a single siRNA or ASO targets multiple or all the viral transcripts (Figure 2). The first RNAi-based drug in clinical trials is ARC-520 (Arrowhead Research Corporation, Pasadena, California, USA), containing a hepatocyte targeted, reversibly masked membrane-active peptide (NAG-MLP) to drive endosomal release of two synthetic RNAi triggers (cholesterol-conjugated siRNAs, siHBV-74 and siHBV-77) which target at HBV X region [64]. A single dosing of ARC-520 reduced serum HBsAg by 1.4 $\pm 0.1$ log10 in NUC-naïve HBeAg positive patients, but only reduced serum HBsAg by approximately 0.3 log10 in NUC-naïve HBeAg negative patients. Further studies revealed that the primary RNA transcripts for HBsAg synthesis are derived from integrated HBV DNA, but not cccDNA, in NUC experienced and NUC-naive HBeAg negative CHB patients and chimpanzees [65]. Due to the lack of the targets of siHBV-74 and siHBV-77 in the RNA transcripts derived from integrated DNA (Figure 2), ARC-520 is much less efficacious in HBeAg negative CHB patients and chimpanzees [65]. As expected, a second-generation siRNA (ARC-521) targeting all HBV transcripts from both cccDNA and integrated DNA significantly reduced HBsAg in HBeAg negative CHB patients [65]. Currently, a new generation of GalNAc-conjugated siRNAs targeting all HBV transcripts, such as JNJ-3989 and AB-729, are well-tolerated in patients with CHB and reduce HBsAg more than 1 log10 IU/mL after a single dosing. Similarly, GalNAc-conjugated ASOs, GSK3389404, is well tolerated to repeated dosing up to 120 mg once a week for 4 weeks in a phase 1 clinical trial [66]. A Phase 2a trial with GSK3228836 showed significant and prolonged reduction of HBV antigenemia after four weeks treatment of CHB patients under NUC treatment or without NUC therapy. It is particularly interesting that GSK3228836 treatment induced more significant reduction and even anti-HBs seroconversion in a portion of NUC-naïve HBeAg-negative, but not HBeAg positive, patients. Asymptomatic and self-resolved ALT flares occurred during HBsAg clearance. While these proof-of-concept studies validated the antiviral efficacy of liver-targeting siRNA and ASOs, the immunological response of HBsAg reduction in patients have not been investigated.

Figure 2.

Transcription maps of cccDNA and integrated HBV DNA. Schematic presentation of HBV RNA transcribed from cccDNA (A) and integrated HBV DNA (B). For the convenience of illustration, cccDNA transcription template is presented as a 1.3mer liner genome. Four promoters (cp: core promoter; sp1: preS1 promoter; sp2: preS2/S promoter and xp: HBx promoter). Epsilon ($ϵ$) RNA element, RNA stem loop (SL$\alpha$), direct repeat sequences 1 and 2 (DR1 and DR2) are presented. Double stranded linear (dsl) DNA is synthesized by in situ priming of plus-stranded DNA and is the primary precursor of integrated viral DNA. Due to the error-prone end processing during the integration via non-homologous end joining DNA repair pathway, deletions and insertions occur in the terminal regions of viral DNA (dashed lines). Due to the loss of 5’-terminal core promoter, the integrated DNA cannot transcribe preC/pgRNA. Because of the loss of the authentic viral poly A adenylation signal at the 3’ terminus, the RNA transcription initiated from sp1, sp2 and xp will extended into host chromosomal DNA and terminated at the encountered poly A adenylation signal. Therefore, all the viral RNA transcripts from integrated DNA are HBV-host cellular chimeras. The binding sites of two siRNA in ARC-520 are indicated.

In addition to the HBV RNA-targeting oligonucleotide therapeutics discussed above, it was found that nucleic acid polymers (NAPs), single-strand phosphorothioate sequence non-specific single-stranded DNA of minimal 40 nucleotides in length, demonstrated superior efficacy to induce the functional cure of chronic hepadnaviral infection in ducks and in human clinical trials [67]. Ducks with persistent duck hepatitis B virus (DHBV) infection after 28 days of REP 2055 treatment lead to initial rapid reductions in serum DHBsAg and DHBV DNA and induction of anti-DHBs antibodies in all ducks, and 6 out of 11 ducks experienced a sustained virologic response at 9 or 16 weeks of follow-up [68]. The clearance of DHBsAg from serum was companied with the significant reduction of HBsAg-positive hepatocytes in the liver. NAPs inhibition of HBsAg secretion in human hepatoma-derived HBV replicating cells (HepG2.2.15) had been demonstrated under the condition of co-treatment with a small molecular compound UNC7938 that promotes the endosomal escaping of NAPs [69]. In a recent phase 2 clinical trial, one of the two forms of NAPs, REP 2139 or REP 2165, was added to CHB patients under TDF and pegylated IFN-α combination therapy for 24 weeks and treated for additional 48 weeks and followed for 24 weeks after the termination of the triple combination therapy [70]. No severe adverse events were reported in patients with NAPs. However, elevated ALT levels were observed during NAP therapy, which was correlated with initial decrease of HBsAg and normalized during therapy and follow-up. At the end of therapy, 24 out of 40 patients achieved the loss of serum HBsAg and serum conversion to anti-HBs. At the end of 24 weeks of follow-up, 14 out of 34 patients remained the negativity of serum HBsAg and can be considered as a “functional” cure [70].

While it is rather intriguing that the combination of standard-of-care CHB therapeutics with NAPs achieved a functional cure in more than 40% of treated patients, the therapeutic efficacy of NAP-based combination therapy requires further validation in expanded clinical trials. It also remains to know whether the improved therapeutic efficacy is due to the inhibition of HBsAg secretion by the NAPs. Apparently, uncovering the immunological mechanism of NAP combination therapy-induced HBsAg seroclearance and seroconversion may reveal the molecular targets for more efficient restoration of functional immune response against HBV in CHB patients and facilitate the improvement of NAPs or discovery of novel therapeutics to functionally cure CHB in a much larger patient population.

Therapeutic potential of monoclonal antibodies for CHB

Humoral immune response to HBV envelop proteins, collectively measured as antibodies against HBsAg, or anti-HBs, becomes detectable after clinical resolution of acute or chronic HBV infection and successful HBV vaccination. Although its role in the resolution of HBV infection remains to be firmly established, the antibody response plays essential roles in the prevention of HBV infection and control of the residual HBV replication after apparent clinical resolution of HBV infection. The tremendous success of antibody drugs in many therapeutic areas and technical development in HBV infection cell cultures and animal models empower the development of monoclonal antibodies targeting HBV envelope proteins as a key therapeutic modality for the management of CHB [71]. As illustrated in Figure 3, many monoclonal antibodies targeting the epitopes located at the N-terminal sodium/taurocholate cotransporting polypeptide (NTCP) receptor binding region in pre-S and antigenic loop of S region have been isolated from B cells derived from individuals who resolved a natural HBV infection or successfully responded to HBV vaccination. These antibodies demonstrated pan-genotype (broadly) or genotype-specific neutralizing activity to HBV infection in HBV infection cell culture assays.

Figure 3.

Distribution of neutralizing epitopes in HBV envelope proteins. The epitopes recognized by human neutralization antibodies against HBV are mapped at the N-terminal NTCP binding region of pre-S1 and antigenic loop of S region. Sequences of these epitopes from Genotype A to I were aligned.

Therapeutically, broadly neutralizing HBV antibodies can block the spread of viral infection and accelerate the clearance of HBV virions and subviral particles from extracellular space. Interestingly, a study showed that a combination of two human monoclonal anti-HBs (HepeX-B) antibodies can also inhibit the release of HBV viral particles from infected cells [72]. The antibodies can additionally recognize viral envelope proteins expressing on the surface of infected hepatocytes and kill the infected cells by natural killer cell-mediated antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). Unfortunately, viral envelope proteins are located primarily at intracellular membranes and not normally expressed in the plasma membrane of hepatocytes at a significant amount, this latter antiviral mechanism should thus not significantly contribute to the therapeutic efficacy of antibody therapies to CHB. In agreement with their immune effector functions, several studies have demonstrated that administration of neutralizing HBV antibodies in multiple HBV-persistent infection mouse models significantly reduced or depleted HBV virions and subviral particles in blood [73–76]. In particular, depletion of circulating HBsAg in AAV-HBV transduced mice enabled the induction of HBV-specific B and T cell immune responses by distinct vaccination strategies [57,77]. Clinically, several human monoclonal antibodies against HBsAg had been shown to significantly reduce viral load and HBsAg antigenemia [72,78]. However, the long-term therapeutic efficacy, particularly in combination with other antiviral agents and immunostimulatory drugs, remains to be evaluated. Interestingly, a recent study showed that engineered anti-influenza virus IgG with enhanced activity to bind a subset of Fc receptor, FcγRIIa, on dendritic cells stimulates dendritic cell maturation and induces protective CD8+ T cell responses to the virus [79]. This finding implies that the broadly neutralizing HBV antibodies may be genetically modified to activate specific dendritic cell and T cell pathway for efficient induction of HBV-specific cellular immune response to durably control the chronic HBV infection.

Summary and perspectives

Although the eradication of HBV cccDNA and/or all the infected hepatocytes to achieve a virological cure of CHB is not entirely impossible, the realistic goal of CHB therapy is the durable off-drug control of residual HBV infection and stop/reverse the liver disease progression, i.e. the functional cure. The biomarker for the functional cure of CHB is the loss of circulating HBsAg. Obviously, unlike the virological cure, the functional cure relies on the constant immune surveillance and control of residue HBV infection. Therefore, restoration or re-establishment of a functional HBV-specific T and B lymphocyte-mediated immune response in the CHB patients is essential to achieve the functional cure. Considering the essential role of viral proteins in driving the differentiation of activated T and B cells toward functional exhaustion, reduction of viral protein expression and elimination of circulating HBsAg and HBeAg is considered as the basis for the reinvigoration of HBV-specific T and B cell immunity. Apparently, due to the extensive metabolic and epigenetic reprogramming of HBV-specific T and B cells in sequential differentiation toward the different degrees of exhaustion status during the long-term chronic infection, it is not surprising that reducing or eliminating HBV antigen stimulation alone is insufficient for the functional recovery of the exhausted T and B cells [80]. However, studies in the various animal models convincingly demonstrated that reduction of intrahepatic and/or circulating HBV antigens does improve the responsiveness of HBV-specific T and B cells to therapeutic vaccination. It will be interesting to further investigate whether the reduced viral antigen load and/or circulating HBsAg and HBeAg also potentiate the therapeutic efficacy of immunostimulating therapy with interferons, PRR agonists and checkpoint blockades. With the advent of therapeutics that can reduce viral protein expression via distinct mechanisms, induce viral protein degradation or accelerate the clearance of circulating HBsAg as well as the development of various novel vaccination strategies and immune-stimulating drugs in next a few years, the best combination therapeutic strategies of viral antigen load reducers and immunostimulators for efficient and safe immune control of chronic HBV infection will likely be discovered.

Funding Statement

Preparation of this manuscript was supported by the Office of the Assistant Secretary of Defense for Health Affairs, through the Peer Reviewed Medical Research Program under Award No. W81XWH-17-1-0600 to Dr. Ju-Tao Guo. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.

Disclosure statement

No potential conflict of interest was reported by the author(s).